FDA staff question benefit of AstraZeneca ovarian cancer drug

June 23, 2014 3:11 PM

9 0

FDA staff question benefit of AstraZeneca ovarian cancer drug

(Reuters) - AstraZeneca Plc's experimental ovarian cancer drug, olaparib, showed an 83 percent reduction in the risk of disease progression, but a U.S. Food and Drug Administration staff review has questioned whether the result could be reproduced.

The company's shares fell 1.8 percent to 43.89 pounds on the London Stock Exchange.

Also read: Trump touts Charter hiring that was in works for two years

Read more

To category page

Loading...